Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1992 Oct;157(4):421–424.

Tuberculosis chemoprophylaxis.

S Salpeter 1
PMCID: PMC1011301  PMID: 1462535

Abstract

The incidence of tuberculosis in the United States, after decreasing for many years, has recently begun to climb at an alarming rate. This rise is due mainly to excess cases in high-risk groups including human immunodeficiency virus-infected patients, the elderly, the foreign born, and the homeless. In the United States tuberculosis has been associated with a 10% mortality despite adequate treatment. The tuberculin skin test is a safe and inexpensive test for detecting tuberculous infection. To improve its predictive value the diagnostic criteria for classifying a positive reaction have recently been revised. High-risk populations should be screened to identify those persons who would most benefit from preventive treatment. Isoniazid therapy taken for 6 to 12 months is a safe and highly effective means of preventing tuberculous infection from developing into active disease. The most worrisome toxicity of isoniazid, fatal hepatitis, is extremely rare; when patients are monitored closely the incidence of death from hepatotoxicity is less than 0.01%.

Full text

PDF
421

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bailey W. C., Taylor S. L., Dascomb H. E., Greenberg H. B., Ziskind M. M. Disturbed hepatic function during isoniazid chemoprophylaxis. Monitoring the hepatic function of 427 hospital employees receiving isoniazid chemoprophylaxis for tuberculosis. Am Rev Respir Dis. 1973 Apr;107(4):523–529. doi: 10.1164/arrd.1973.107.4.523. [DOI] [PubMed] [Google Scholar]
  2. Barnes P. F., Bloch A. B., Davidson P. T., Snider D. E., Jr Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1991 Jun 6;324(23):1644–1650. doi: 10.1056/NEJM199106063242307. [DOI] [PubMed] [Google Scholar]
  3. Byrd R. B., Horn B. R., Solomon D. A., Griggs G. A. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients. JAMA. 1979 Mar 23;241(12):1239–1241. [PubMed] [Google Scholar]
  4. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 44-1991. A 17-year-old Cambodian girl with recurrent abdominal pain and a tender mass in the right lower quadrant. N Engl J Med. 1991 Oct 31;325(18):1295–1302. doi: 10.1056/NEJM199110313251807. [DOI] [PubMed] [Google Scholar]
  5. Comstock G. W. Prevention of tuberculosis among tuberculin reactors: maximizing benefits, minimizing risks. JAMA. 1986 Nov 21;256(19):2729–2730. [PubMed] [Google Scholar]
  6. Dutt A. K., Moers D., Stead W. W. Smear- and culture-negative pulmonary tuberculosis: four-month short-course chemotherapy. Am Rev Respir Dis. 1989 Apr;139(4):867–870. doi: 10.1164/ajrccm/139.4.867. [DOI] [PubMed] [Google Scholar]
  7. Dutt A. K., Moers D., Stead W. W. Smear-negative, culture-positive pulmonary tuberculosis. Six-month chemotherapy with isoniazid and rifampin. Am Rev Respir Dis. 1990 May;141(5 Pt 1):1232–1235. doi: 10.1164/ajrccm/141.5_Pt_1.1232. [DOI] [PubMed] [Google Scholar]
  8. Franks A. L., Binkin N. J., Snider D. E., Jr, Rokaw W. M., Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep. 1989 Mar-Apr;104(2):151–155. [PMC free article] [PubMed] [Google Scholar]
  9. Glassroth J., Bailey W. C., Hopewell P. C., Schecter G., Harden J. W. Why tuberculosis is not prevented. Am Rev Respir Dis. 1990 May;141(5 Pt 1):1236–1240. doi: 10.1164/ajrccm/141.5_Pt_1.1236. [DOI] [PubMed] [Google Scholar]
  10. Glassroth J., Robins A. G., Snider D. E., Jr Tuberculosis in the 1980s. N Engl J Med. 1980 Jun 26;302(26):1441–1450. doi: 10.1056/NEJM198006263022603. [DOI] [PubMed] [Google Scholar]
  11. Grosset J. Present and new drug regimens in chemotherapy and chemoprophylaxis of tuberculosis. Bull Int Union Tuberc Lung Dis. 1990 Jun-Sep;65(2-3):86–91. [PubMed] [Google Scholar]
  12. Grzybowski S., Ashley M. J., Pinkus G. Chemoprophylaxis in inactive tuberculosis: long-term evaluation of a Canadian trial. Can Med Assoc J. 1976 Apr 3;114(7):607–611. [PMC free article] [PubMed] [Google Scholar]
  13. Hamrick R. M., 3rd, Yeager H., Jr Tuberculosis update. Am Fam Physician. 1988 Oct;38(4):205–213. [PubMed] [Google Scholar]
  14. Kopanoff D. E., Snider D. E., Jr, Caras G. J. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978 Jun;117(6):991–1001. doi: 10.1164/arrd.1978.117.6.991. [DOI] [PubMed] [Google Scholar]
  15. Lecoeur H. F., Truffot-Pernot C., Grosset J. H. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis. 1989 Nov;140(5):1189–1193. doi: 10.1164/ajrccm/140.5.1189. [DOI] [PubMed] [Google Scholar]
  16. Mehta J. B., Dutt A. K., Harvill L., Henry W. Isoniazid preventive therapy for tuberculosis. Are we losing our enthusiasm? Chest. 1988 Jul;94(1):138–141. doi: 10.1378/chest.94.1.138. [DOI] [PubMed] [Google Scholar]
  17. Perez-Stable E. J., Slutkin G., Paz E. A., Hopewell P. C. Tuberculin reactivity in United States and foreign-born Latinos: results of a community-based screening program. Am J Public Health. 1986 Jun;76(6):643–646. doi: 10.2105/ajph.76.6.643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pérez-Stable E. J., Hopewell P. C. Current tuberculosis treatment regimens. Choosing the right one for your patient. Clin Chest Med. 1989 Sep;10(3):323–339. [PubMed] [Google Scholar]
  19. Rabindran E., Matuszak D. L., Israel E., Woodall H., Highsmith H., Flynn J. Preventive therapy for tuberculosis in Maryland. Md Med J. 1991 Sep;40(9):793–797. [PubMed] [Google Scholar]
  20. Rieder H. L., Cauthen G. M., Kelly G. D., Bloch A. B., Snider D. E., Jr Tuberculosis in the United States. JAMA. 1989 Jul 21;262(3):385–389. [PubMed] [Google Scholar]
  21. Rose D. N., Schechter C. B., Fahs M. C., Silver A. L. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis. Am J Prev Med. 1988 Mar-Apr;4(2):102–109. [PubMed] [Google Scholar]
  22. Rose D. N., Schechter C. B., Silver A. L. The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors. JAMA. 1986 Nov 21;256(19):2709–2713. [PubMed] [Google Scholar]
  23. Schieffelbein C. W., Jr, Snider D. E., Jr Tuberculosis control among homeless populations. Arch Intern Med. 1988 Aug;148(8):1843–1846. [PubMed] [Google Scholar]
  24. Selwyn P. A., Hartel D., Lewis V. A., Schoenbaum E. E., Vermund S. H., Klein R. S., Walker A. T., Friedland G. H. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989 Mar 2;320(9):545–550. doi: 10.1056/NEJM198903023200901. [DOI] [PubMed] [Google Scholar]
  25. Slutkin G., Perez-Stable E. J., Hopewell P. C. Time course and boosting of tuberculin reactions in nursing home residents. Am Rev Respir Dis. 1986 Nov;134(5):1048–1051. doi: 10.1164/arrd.1986.134.5.1048. [DOI] [PubMed] [Google Scholar]
  26. Small P. M., Schecter G. F., Goodman P. C., Sande M. A., Chaisson R. E., Hopewell P. C. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1991 Jan 31;324(5):289–294. doi: 10.1056/NEJM199101313240503. [DOI] [PubMed] [Google Scholar]
  27. Snider D. E., Jr, Caras G. J., Koplan J. P. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA. 1986 Mar 28;255(12):1579–1583. [PubMed] [Google Scholar]
  28. Stead W. W., Lofgren J. P., Warren E., Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med. 1985 Jun 6;312(23):1483–1487. doi: 10.1056/NEJM198506063122304. [DOI] [PubMed] [Google Scholar]
  29. Stead W. W., To T., Harrison R. W., Abraham J. H., 3rd Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med. 1987 Dec;107(6):843–845. doi: 10.7326/0003-4819-107-6-843. [DOI] [PubMed] [Google Scholar]
  30. Stead W. W., To T. The significance of the tuberculin skin test in elderly persons. Ann Intern Med. 1987 Dec;107(6):837–842. doi: 10.7326/0003-4819-107-6-837. [DOI] [PubMed] [Google Scholar]
  31. Thompson N. J., Glassroth J. L., Snider D. E., Jr, Farer L. S. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis. 1979 Apr;119(4):587–597. doi: 10.1164/arrd.1979.119.4.587. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES